BridgeBio Pharma (BBIO) Earnings Analysis

BridgeBio Pharma (BBIO) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.84 USD vs -0.67877 USD est (-23.8%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -22.04.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BBIO next report earnings?

No confirmed upcoming earnings date is currently scheduled for BBIO. This page updates as the calendar is published.

BBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.84 USD-0.67877 USD-23.8%Miss
2025-10-29-0.95 USD-0.88 USD-8%Miss
2025-02-20-1.31 USD-1.09 USD-20.2%Miss
2024-08-01-1.02 USD-1.09 USD+6.4%Beat

Beat rate: 1/4 (25%) over reported quarters with consensus data.

BBIO valuation and analyst view

Trailing P/E-22.04
Trailing EPS-3.72672 USD
Price / book-7.10
Dividend yield0.00%
Market cap16.09B
Analyst consensusBuy (23 buy / 3 hold / 0 sell)
Avg price target109.25 USD

Related research pages

Frequently asked questions

When is BridgeBio Pharma (BBIO)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for BBIO. This page updates as the calendar is published.

Did BBIO beat earnings last quarter?

In its 2026-05-07 report, BBIO posted EPS of -0.84 USD versus a -0.67877 USD estimate — a miss of 23.8%.

What is BBIO's earnings track record?

Over the last 4 reported quarters with consensus data, BBIO beat estimates 1 times (25%).

What is BBIO's current P/E ratio and EPS?

BBIO trades at a trailing P/E of -22.04 on trailing EPS of -3.726717921104502 USD.

What do analysts rate BBIO?

Analyst consensus is "Buy" across 26 ratings (0 strong buy, 23 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 109.25 USD.